Gu, Yanhong

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade

Zhao, M., Guo, W., Wu, Y., Yang, C., Zhong, L., Deng, G., Zhu, Y., Liu, W., Gu, Y., Lu, Y., et al. (2019) · Acta Pharmaceutica Sinica B

Protein Tyrosine PhosphatasesCancer Immunotherapy and Biomarkers

Cited by 190

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial

Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., et al. (2025) · Nature Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 42

Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

Li, J., Wang, Z., Huang, J., Ba, Y., Cao, B., Luo, S., Li, W., Bai, C., Song, Z., Xiong, J., et al. (2026) · The Lancet Gastroenterology & Hepatology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 3